title: [Diagnosis and treatment of octogenarian neoplastic patients: bladder cancers].
abstract: Age is a risk factor for the occurrence of bladder cancer and bladder cancer is a disease of the elderly. The choice of treatment relays on the staging into non-invasive and muscle-invasive bladder cancer. Non-invasive bladder cancer is usually treated with transurethral resection of the bladder (TURB) followed by intravesical therapy with BCG or chemotherapeutic agents. The gold standard in the treatment of muscle-invasive bladder cancer is radical cystectomy. The elderly and, in particular, the octogenarian have a worse tolerance for aggressive therapies, due to the higher incidence of side effects and complications. This problem could significantly occur for intravesical BCG therapy and for radical cystectomy. When the urologist faces the treatment of an octogenarian affected by bladder cancer, he should answer many questions: 1. In case of a non-invasive bladder cancer, is it possible to use the same drugs that we use for younger patients (BCG vs chemotherapeutic agents)? Should the timing and the kind of follow-up be the same? 2. Should the octogenarian affected by muscle-invasive bladder cancer undergo radical cystectomy or a less invasive treatment? What kind of diversion should be preferred? Is it possible to propose an orthotopic neobladder to an octogenarian patient? The choice of the treatment should be made on the basis of a careful evaluation of the patient, considering not only the patient's age but also comorbidities and life expectancy.
authors.affiliation: Divisione Universitaria di Urologia 2, Ospedale San Giovanni Battista Molinette, Torino, Italy. pdestefanis2@molinette.piemonte.it
authors.forename: Paolo
authors.initials: P
authors.lastname: Destefanis
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bisconti
authors.forename: Fedele
authors.initials: F
authors.lastname: Lasaponara
authors.forename: Dario
authors.initials: D
authors.lastname: Fontana
mesh_terms: D000283:Administration, Intravesical; D000367:Age Factors; D017668:Age of Onset; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D015653:Cystectomy; D005260:Female; D006801:Humans; D008017:Life Expectancy; D008297:Male; D009361:Neoplasm Invasiveness; D010342:Patient Acceptance of Health Care; D018579:Patient Selection; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D014547:Urinary Diversion
chemical_list: D001500:BCG Vaccine